PMID- 32185666
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 2629-3277 (Electronic)
IS  - 2629-3269 (Print)
IS  - 2629-3277 (Linking)
VI  - 16
IP  - 3
DP  - 2020 Jun
TI  - Energy Metabolism Analysis of Three Different Mesenchymal Stem Cell Populations 
      of Umbilical Cord Under Normal and Pathologic Conditions.
PG  - 585-595
LID - 10.1007/s12015-020-09967-8 [doi]
AB  - Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a pivotal source of 
      therapeutically active cells for regenerative medicine due to their multipotent 
      differentiation potential, immunomodulatory and anti-inflammatory proprieties, as 
      well as logistical collection advantages without ethical concerns. However, it 
      remains poorly understood whether MSCs from different compartments of the human 
      umbilical cord are therapeutically superior than others. In this study, MSCs were 
      isolated from Wharton's jelly (WJ-MSCs), perivascular region (PV-MSCs) and cord 
      lining (CL-MSCs) of hUC. These cells expressed the mesenchymal markers (CD90, 
      CD73), stemness marker (OCT4), endothelial cell adhesion molecular marker 
      (CD146), and the monocyte/macrophage marker (CD14) found within the MSC 
      population implicated as a key regulator of inflammatory responses to hypoxia, 
      was displayed by WJ-, PV-, and CL-MSCs respectively. A direct consequence of 
      oxygen and glucose deprivation during stroke and reperfusion is impaired 
      mitochondrial function that contributes to cellular death. Emerging findings of 
      mitochondria transfer provide the basis for the replenishment of healthy 
      mitochondria as a strategy for the treatment of stroke. Cell Energy Phenotype and 
      Mito Stress tests were performed the energy metabolic profile of the three MSC 
      populations and their mitochondrial function in both ambient and OGD cell culture 
      conditions. PV-MSCs showed the highest mitochondrial activity. CL-MSCs were the 
      least affected by OGD/R condition, suggesting their robust survival in ischemic 
      environment. In this study, MSC populations in UC possess comparable metabolic 
      capacities and good survival under normal and hypoxic conditions suggesting their 
      potential as transplantable cells for mitochondrial-based stem cell therapy in 
      stroke and other ischemic diseases.
FAU - Russo, Eleonora
AU  - Russo E
AD  - Department of Neurosurgery and Brain Repair, University of South Florida Morsani 
      College of Medicine, Tampa, Florida, USA.
AD  - Section of Histology and Embryology, Department of Biomedicine, Neurosciences and 
      Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy.
FAU - Lee, Jea-Young
AU  - Lee JY
AD  - Department of Neurosurgery and Brain Repair, University of South Florida Morsani 
      College of Medicine, Tampa, Florida, USA.
FAU - Nguyen, Hung
AU  - Nguyen H
AD  - Department of Neurosurgery and Brain Repair, University of South Florida Morsani 
      College of Medicine, Tampa, Florida, USA.
FAU - Corrao, Simona
AU  - Corrao S
AD  - Section of Histology and Embryology, Department of Biomedicine, Neurosciences and 
      Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy.
FAU - Anzalone, Rita
AU  - Anzalone R
AD  - Department of Surgical, Oncological and Stomatological Sciences, University of 
      Palermo, Palermo, Italy.
FAU - La Rocca, Giampiero
AU  - La Rocca G
AD  - Section of Histology and Embryology, Department of Biomedicine, Neurosciences and 
      Advanced Diagnostics (BIND), University of Palermo, Palermo, Italy. 
      giampylr@hotmail.com.
FAU - Borlongan, Cesar V
AU  - Borlongan CV
AD  - Department of Neurosurgery and Brain Repair, University of South Florida Morsani 
      College of Medicine, Tampa, Florida, USA. cborlong@health.usf.edu.
LA  - eng
GR  - R01 NS090962/NS/NINDS NIH HHS/United States
GR  - R21 NS109575/NS/NINDS NIH HHS/United States
GR  - R01 NS102395/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Stem Cell Rev Rep
JT  - Stem cell reviews and reports
JID - 101752767
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/metabolism
MH  - Cell Shape
MH  - Cell Survival
MH  - *Energy Metabolism
MH  - Humans
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Mitochondria/metabolism
MH  - Umbilical Cord/*pathology
MH  - Wharton Jelly/cytology
PMC - PMC7253397
OTO - NOTNLM
OT  - Bioenergetics
OT  - Ischemic diseases
OT  - Mitochondria
OT  - Perivascular
OT  - Stem cell therapy
OT  - Stroke
OT  - Umbilical cord mesenchymal stem cells
OT  - Wharton's Jelly
COIS- Dr Borlongan is funded and received royalties and stock options from Astellas, 
      Asterias, Sanbio, Athersys, KMPHC, and International Stem Cell Corporation; and 
      also received consultant compensation for Chiesi Farmaceutici. He also holds 
      patents and patent applications related to stem cell biology and therapeutic 
      applications.
EDAT- 2020/03/19 06:00
MHDA- 2021/06/04 06:00
PMCR- 2020/03/17
CRDT- 2020/03/19 06:00
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/03/19 06:00 [entrez]
PHST- 2020/03/17 00:00 [pmc-release]
AID - 10.1007/s12015-020-09967-8 [pii]
AID - 9967 [pii]
AID - 10.1007/s12015-020-09967-8 [doi]
PST - ppublish
SO  - Stem Cell Rev Rep. 2020 Jun;16(3):585-595. doi: 10.1007/s12015-020-09967-8.